Literature DB >> 12195437

Impact of brain tumour treatment on quality of life.

Jan J Heimans1, Martin J B Taphoorn.   

Abstract

Measurement of Health Related Quality of Life (HRQL) in brain tumour patients is important because brain tumours and brain tumour treatment usually affect physical, cognitive as well as emotional functioning. Measurement of HRQL is important for the understanding of disease burden and for the impact of specific tumour treatment. Quality of Life is a multidimensional concept consisting of physical, psychological and social phenomena. A large number of Quality of Life instruments have been developed. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the MOS Short-Form Health Survey are two frequently used general HRQL instruments. A specific brain tumour scale is the Brain Cancer Module, which is designed to be used in combination with general questionnaires. HRQL measurement and neuropsychological examination were used to investigate the impact of radiotherapy and surgery in low-grade glioma patients and the influence of tumour volume, tumour localization, performance status and age in both low-grade and high-grade glioma patients.

Entities:  

Mesh:

Year:  2002        PMID: 12195437     DOI: 10.1007/s00415-002-0839-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  46 in total

1.  Health-related quality of life in high-grade glioma patients: a prospective single-center study.

Authors:  Cagdas Yavas; Faruk Zorlu; Gokhan Ozyigit; Murat Gurkaynak; Guler Yavas; Deniz Yuce; Mustafa Cengiz; Ferah Yildiz; Fadil Akyol
Journal:  Support Care Cancer       Date:  2011-12-13       Impact factor: 3.603

2.  Quality of life and physical limitations in primary brain tumor patients.

Authors:  Mariana R Gazzotti; Suzana M F Malheiros; Marcela Batan Alith; Oliver Nascimento; Ilka Lopes Santoro; José R Jardim; Milena Vidotto
Journal:  Qual Life Res       Date:  2011-04-22       Impact factor: 4.147

Review 3.  Systematic review of supportive care needs in patients with primary malignant brain tumors.

Authors:  Elizabeth Ford; Susan Catt; Anthony Chalmers; Lesley Fallowfield
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

4.  Symptoms and medication management in the end of life phase of high-grade glioma patients.

Authors:  J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

5.  Assessment of verbal working memory before and after surgery for low-grade glioma.

Authors:  Pilar Teixidor; Peggy Gatignol; Marianne Leroy; Cristina Masuet-Aumatell; Laurent Capelle; Hugues Duffau
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

Review 6.  Molecular profiling in glioblastoma: prelude to personalized treatment.

Authors:  Nikol Mladkova; Arnab Chakravarti
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

7.  Late effects in survivors of central nervous system tumors: reports by patients and proxies.

Authors:  Kelly Sloane; Carolyn Vachani; Margaret K Hampshire; James M Metz; Christine E Hill-Kayser
Journal:  J Cancer Surviv       Date:  2015-07-15       Impact factor: 4.442

8.  Occurrence and predictors of the fatigue in high-grade glioma patients.

Authors:  Irene Aprile; Silvia Chiesa; Luca Padua; Chiara Di Blasi; Maria Felice Arezzo; Vincenzo Valentini; Enrico Di Stasio; Mario Balducci
Journal:  Neurol Sci       Date:  2015-02-20       Impact factor: 3.307

Review 9.  Neuro-oncology and palliative care: a challenging interface.

Authors:  Esther Lin; Mark A Rosenthal; Brian H Le; Peter Eastman
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

10.  Risk for unemployment at 10 years following cancer diagnosis among very long-term survivors: a population based study.

Authors:  Yakir Rottenberg; Angela G E M de Boer
Journal:  J Cancer Surviv       Date:  2020-02-14       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.